UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

[1]  G. Baiocchi,et al.  Risk factors for pelvic and distant recurrence in locally advanced cervical cancer. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[2]  H. Makino,et al.  Multi‐institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: A Kansai Clinical Oncology Group study (KCOG‐G1201) , 2019, The journal of obstetrics and gynaecology research.

[3]  Kathleen R. Cho,et al.  Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  T. Enomoto,et al.  Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010 , 2018, The journal of obstetrics and gynaecology research.

[5]  M. Kaneuchi,et al.  Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer , 2018, International Journal of Clinical Oncology.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  T. Enomoto,et al.  Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067). , 2018, Gynecologic oncology.

[8]  R. Mathijssen,et al.  Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics , 2018, Clinical Pharmacokinetics.

[9]  Young Seok Kim,et al.  The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04) , 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[10]  V. Ellingrod,et al.  Germline genetic variants with implications for disease risk and therapeutic outcomes. , 2017, Physiological genomics.

[11]  M. Shimada,et al.  Comparison of adjuvant therapy for node‐positive clinical stage IB‐IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation , 2017, International journal of cancer.

[12]  B. Seagle,et al.  Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study. , 2017, Gynecologic oncology.

[13]  Jian Li,et al.  Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis , 2017, BMC Cancer.

[14]  M. Takano,et al.  UGT1A1 polymorphisms in cancer: impact on irinotecan treatment , 2017, Pharmacogenomics and personalized medicine.

[15]  T. Hachisuga,et al.  Clinical statistics of gynecologic cancers in Japan , 2017, Journal of gynecologic oncology.

[16]  T. Sugiyama,et al.  Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass , 2016, International Journal of Clinical Oncology.

[17]  Jung-Woo Park,et al.  Prognostic significance of positive lymph node number in early cervical cancer. , 2016, Molecular and clinical oncology.

[18]  Y. Ohashi,et al.  Impact of UGT1A1 genotype upon toxicities of combination with low‐dose irinotecan plus platinum , 2016, Asia-Pacific journal of clinical oncology.

[19]  Y. Hirashima,et al.  Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy , 2016, International Journal of Clinical Oncology.

[20]  N. Matsumura,et al.  Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer , 2016, The Journal of international medical research.

[21]  N. Matsumura,et al.  Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients , 2015, BMC Cancer.

[22]  Yong-Man Kim,et al.  Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting , 2015, PloS one.

[23]  Tsuyoshi Saito,et al.  Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer , 2015, International Journal of Clinical Oncology.

[24]  M. Morita,et al.  Cost of illness of the Cervical Cancer of the uterus in Japan - a time trend and future projections , 2015, BMC Health Services Research.

[25]  J. Pignon,et al.  The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis , 2014, The Pharmacogenomics Journal.

[26]  K. Kosaki,et al.  Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients , 2013, Journal of Human Genetics.

[27]  Jianming Xu,et al.  UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. , 2012, World journal of gastroenterology.

[28]  N. Yaegashi,et al.  Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065). , 2012, Oncology reports.

[29]  F. Akiyama,et al.  Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy. , 2010, Gynecologic oncology.

[30]  K. Hornik,et al.  Unbiased Recursive Partitioning: A Conditional Inference Framework , 2006 .

[31]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[32]  N. Sakuragi,et al.  Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy , 1999, Cancer.

[33]  T. Inoue,et al.  The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB , 1990, Cancer.